Literature DB >> 8763269

Increased serum laminin and angiogenin concentrations in patients with peripheral arterial occlusive disease.

H Burgmann1, U Hollenstein, T Maca, K Zedwitz-Liebenstein, F Thalhammer, R Koppensteiner, H Ehringer, W Graninger.   

Abstract

AIM: To measure serum laminin and angiogenin concentrations in patients with peripheral arterial occlusive disease (PAOD) Fontaine stages IIb, III, and IV.
METHODS: The study population comprised 38 patients (20 men and 18 women) with stage IV PAOD, 11 patients (six men and five women) with stage III PAOD, 18 patients (10 men and eight women) with stage IIb PAOD, and 23 patients (10 men and 13 women) with deep vein thrombosis. Fifteen normal subjects (matched for risk factors) and 10 patients (five men and five women) without PAOD served as controls. Serum samples were obtained at admission and serum laminin and angiogenin concentrations were measured using an enzyme linked immunosorbent assay.
RESULTS: Patients with stage IV PAOD had higher serum laminin (mean +/- SEM; 826 +/- 97 ng/ml) and angiogenin concentrations (467 +/- 26 pg/ml) than normal subjects (laminin: 379 +/- 21 ng/ml; angiogenin: 358 +/- 16 pg/ml) and patients without PAOD (laminin: 277 +/- 34 ng/ml; angiogenin: 406 +/- 25 pg/ml). A significant correlation was found between angiogenin and laminin and between serum laminin and fibrinogen concentrations in patients with stage IV disease.
CONCLUSIONS: Raised laminin and angiogenin concentrations may be indicators of endothelial damage caused by reduced vascular perfusion or compensatory revascularisation, or both.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8763269      PMCID: PMC500545          DOI: 10.1136/jcp.49.6.508

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  18 in total

1.  Laminin--a glycoprotein from basement membranes.

Authors:  R Timpl; H Rohde; P G Robey; S I Rennard; J M Foidart; G R Martin
Journal:  J Biol Chem       Date:  1979-10-10       Impact factor: 5.157

Review 2.  Angiogenesis under normal and pathological conditions.

Authors:  D Ribatti; A Vacca; L Roncali; F Dammacco
Journal:  Haematologica       Date:  1991 Jul-Aug       Impact factor: 9.941

3.  Relation of plasma coagulation factor VII and fibrinogen to carotid artery intima-media thickness.

Authors:  M N Sosef; J G Bosch; J van Oostayen; T Visser; J H Reiber; F R Rosendaal
Journal:  Thromb Haemost       Date:  1994-08       Impact factor: 5.249

4.  Serum laminin in Graves' disease.

Authors:  C Wenisch; D Myskiw; E Narzt; E Presterl; W Graninger
Journal:  Eur J Clin Invest       Date:  1995-06       Impact factor: 4.686

Review 5.  Fibrinogen and fibrin in the arterial wall.

Authors:  A Bini; B J Kudryk
Journal:  Thromb Res       Date:  1994-08-01       Impact factor: 3.944

Review 6.  Serum laminin in hepatosplenic human schistosomiasis.

Authors:  E R Parise; M M Leite-Mór; H Rosa
Journal:  Mem Inst Oswaldo Cruz       Date:  1992       Impact factor: 2.743

Review 7.  Fibrinogen as a cardiovascular risk factor--interrelationship with infections and inflammation.

Authors:  E Ernst
Journal:  Eur Heart J       Date:  1993-12       Impact factor: 29.983

8.  Serum laminin P1 in idiopathic myelofibrosis and related diseases.

Authors:  H Hasselbalch; P Junker
Journal:  Leuk Res       Date:  1994-08       Impact factor: 3.156

9.  Relation of laboratory and clinical variables to the grade of carotid atherosclerosis.

Authors:  I G Szirmai; A Kamondi; H Magyar; C Juhász
Journal:  Stroke       Date:  1993-12       Impact factor: 7.914

10.  Serum laminin in malaria.

Authors:  C Wenisch; W Graninger; C Viravan; S Looareesuwan; B Parschalk; W Wernsdorfer
Journal:  J Clin Pathol       Date:  1994-09       Impact factor: 3.411

View more
  8 in total

1.  Adverse effects of bone marrow stromal cell treatment of stroke in diabetic rats.

Authors:  Jieli Chen; Xinchun Ye; Tao Yan; Chunling Zhang; Xiao-Ping Yang; Xu Cui; Yishen Cui; Alex Zacharek; Cynthia Roberts; Xinfeng Liu; Xiangguo Dai; Mei Lu; Michael Chopp
Journal:  Stroke       Date:  2011-09-22       Impact factor: 7.914

2.  Homocysteine and laminin are not prognostic markers in patients with septic inflammatory response syndrome.

Authors:  B Stoiser; F Thalhammer; I El-Menyawi; A Wilfing; F Daxböck; G J Locker; H Burgmann
Journal:  Clin Diagn Lab Immunol       Date:  2000-01

3.  Serum angiogenin in inflammatory bowel disease.

Authors:  Ioannis E Koutroubakis; Costas Xidakis; Konstantinos Karmiris; Aekaterini Sfiridaki; Ermioni Kandidaki; Elias A Kouroumalis
Journal:  Dig Dis Sci       Date:  2004 Nov-Dec       Impact factor: 3.199

4.  Serum laminin and collagen IV in inflammatory bowel disease.

Authors:  I E Koutroubakis; E Petinaki; P Dimoulios; E Vardas; M Roussomoustakaki; A N Maniatis; E A Kouroumalis
Journal:  J Clin Pathol       Date:  2003-11       Impact factor: 3.411

5.  The relationship between serum levels of angiogenin, bFGF, VEGF, and ocular involvement in patients with Behçet's disease.

Authors:  Ali Yalçındağ; Yeşim Gedik-Oğuz; F Nilüfer Yalçındağ
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-04-04       Impact factor: 3.117

Review 6.  Three decades of research on angiogenin: a review and perspective.

Authors:  Jinghao Sheng; Zhengping Xu
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2015-12-23       Impact factor: 3.848

7.  GSTM1 Modulates Expression of Endothelial Adhesion Molecules in Uremic Milieu.

Authors:  Djurdja Jerotic; Sonja Suvakov; Marija Matic; Abdelrahim Alqudah; David J Grieve; Marija Pljesa-Ercegovac; Ana Savic-Radojevic; Tatjana Damjanovic; Nada Dimkovic; Lana McClements; Tatjana Simic
Journal:  Oxid Med Cell Longev       Date:  2021-01-25       Impact factor: 6.543

8.  Niaspan attenuates the adverse effects of bone marrow stromal cell treatment of stroke in type one diabetic rats.

Authors:  Tao Yan; Xinchun Ye; Michael Chopp; Alex Zacharek; Ruizhuo Ning; Poornima Venkat; Cynthia Roberts; Mei Lu; Jieli Chen
Journal:  PLoS One       Date:  2013-11-26       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.